Binter

Quick links to important sections

Binter

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Binter

What is Binter? A Medication Overview

Binter is a medication formulated with the active component Terbinafine Hydrochloride, a chemical entity designed to manage infections caused by specific fungal organisms. This medication is primarily defined as a synthetic compound belonging to the allylamine antifungal group, classifying it as an antimycotic agent. Terbinafine Hydrochloride is recognized as the established International Nonproprietary Name (INN) for this substance, confirming its identity as a single-ingredient product. The oral tablet form of Terbinafine is typically reserved for more entrenched conditions, such as fungal infections affecting the nail.


Quick Facts: Binter (Terbinafine Hydrochloride)

Property Description
Active Ingredient Terbinafine Hydrochloride
Forms Tablets (oral) and Topical (creams, solutions)
Pharmacological Class Allylamine Antifungal (Antimycotic Agent)
General Purpose To eliminate fungal pathogens
Origin Synthetic compound

1. Defining Binter: Classification and Active Ingredient

Binter is formally classified within the allylamine antifungal group, a classification based on the specific chemical structure of its active ingredient, Terbinafine Hydrochloride. This classification signifies that the substance is effective against fungi, particularly the dermatophytes responsible for infections of the skin, hair, and nails. Unlike older agents, Terbinafine is a synthetic compound specifically engineered for its therapeutic purpose, confirming its established role as a specialized antifungal agent. The compound is characterized by its focused efficacy against a common spectrum of fungal pathogens.

2. Forms, Administration Type, and General Utility

Binter is made available in several dosage forms, which include tablets intended for oral administration (systemic treatment) and various topical preparations, such as creams, solutions, and gels (local treatment). The utility of Binter stems from the necessity to directly confront fungal pathogens. The medication is designed to reduce the burden of pathogenic fungi in various tissues. This medicine is intended to clear the underlying fungal source of an infection. The availability of both systemic and local pharmaceutical preparations ensures that the active ingredient can be delivered effectively, providing a versatile option for addressing the pathological state caused by fungal overgrowth.

3. High-Level Action: The Fungicidal Principle

The principal function of Binter is its defining fungicidal action, meaning it works to eliminate the causative fungal organisms rather than merely slowing their reproduction. This effect is achieved through the Terbinafine Hydrochloride interfering with the integrity of the fungal cell membrane. The mechanism involves disrupting the fungal cell's structure, thereby killing the pathogen. Terbinafine works by directly attacking and disrupting the fungal cell membrane. By targeting and disrupting the fungal cell's structure, Binter fulfills its general purpose: to clear the infection and resolve the symptoms associated with the presence of pathogenic fungi.

Regulatory References

  1. Terbinafine Hydrochloride Labeling (NIH/DailyMed)
  2. Terbinafine - StatPearls (NIH)

What side effects are possible with Binter?

Possible Side Effects and Safety Information for Binter

This section outlines the officially documented side effects and safety concerns related to Binter, based strictly on governmental regulatory documents.

Adverse Reaction Profile

Classification Details (As documented in Regulatory Sources)
Most Common Adverse Reactions The official regulatory documentation does not specify the most common or frequently occurring adverse reactions for Binter.
Serious Adverse Reactions No specific serious or clinically significant adverse reactions (e.g., organ system damage, life-threatening events) have been explicitly detailed in publicly available regulatory summaries for Binter.
System-Organ Classes The body systems (e.g., gastrointestinal, nervous, cardiovascular) most frequently affected by Binter are not documented in current public regulatory summaries.
Frequency Framework A formal frequency classification system (such as Very Common, Common, Uncommon, etc., typically defined by regulatory bodies like the EMA) is not available for Binter.

Population and Safety Restrictions

  • Population-Specific Safety: Official regulatory safety profiles do not currently detail any unique safety considerations for specific populations (e.g., geriatric patients, those with renal impairment, or specific pediatric groups). Safety must be managed on a case-by-case basis based on the prescribing information.
  • Dose- or Exposure-Related Patterns: Any specific patterns where the frequency or severity of side effects increases with higher doses or prolonged exposure are not formally stated in regulatory summaries for Binter.
  • Safety-Related Limitations: No explicit safety-related restrictions or limitations (such as contraindications or precautions for use with certain pre-existing conditions) are available in the public regulatory data for Binter.

High-Level Safety Summary

Regulatory agencies utilize comprehensive risk management plans to ensure that any potential risks of a medicine are properly characterized and communicated. The complete regulatory safety summary, including all formal warnings, precautions, and a full list of adverse events, is contained within the official prescribing information, which serves as the authoritative source for the Binter safety profile. Understanding the safety profile relies entirely on this formal, controlled labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Binter (Terbinafine Hydrochloride) defines the official overdose profile based on reported clinical experience and mandates specific emergency actions for severe toxicity.


Documented Overdose Manifestations

Reported symptoms following acute oral overdose, even at high doses (up to 5 grams), have generally involved non-serious reactions. These documented manifestations include nausea, vomiting, abdominal pain, dizziness, headache, rash, and frequent urination. The clinical profile is focused on the gastrointestinal, nervous, and integumentary systems. No specific antidote is known for managing Binter overdose; management is non-specific.


Official Emergency Actions

Regulators mandate that patients seek immediate medical attention for certain severe symptoms. Patients must be warned to report immediately to their physician any signs suggestive of severe liver injury, such as jaundice, persistent nausea, dark urine, or pale stools. Such symptoms require immediate discontinuation of the medication and prompt medical evaluation of liver function.

Official supportive management procedures include the administration of activated charcoal to reduce drug absorption and providing necessary symptomatic supportive therapy. The drug's elimination rate is reduced in individuals with pre-existing renal or hepatic impairment, which is a consideration in overdose management.

Therapeutic Uses of Binter

What Binter treats: main uses and benefits

The primary therapeutic domain of Binter is relevant for easing symptoms related to systemic imbalance and those symptoms that interfere with daily comfort. This type of therapy is considered relevant in conditions characterized by periods of heightened symptoms, often involving episodic or fluctuating manifestations, applied when functional stability becomes affected. For example, Benztropine, a medication in this category, assists with difficulties with movement, muscle control, and balance, and is used for managing drug-induced tremors and muscle rigidity. This medication category may assist with treating symptoms of Parkinson's disease and other specific motor issues.

This approach is particularly valuable in scenarios where additional symptomatic support is needed, primarily focusing on easing the overall symptom burden. The clinical context is often one marked by temporary physiological imbalance.

“It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.”

The therapy supports patients during difficult episodes by assisting with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for symptoms of increased neurological or muscular activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Binter (benztropine mesylate) is primarily used to treat the symptoms of Parkinson's disease and certain movement disorders (extrapyramidal symptoms) caused by antipsychotic medications. It works by decreasing the activity of acetylcholine, a natural substance in the body.


Contraindications

Binter should generally not be used in the following circumstances:

  • Children under three years of age due to an increased risk of atropine-like side effects.
  • Patients with a known history of hypersensitivity or allergic reaction to benztropine or any component of the formulation.
  • Patients with angle-closure glaucoma.
  • Patients with tardive dyskinesia, as the medication may worsen this condition.

Use With Caution

Caution and close medical supervision are advised for individuals with certain pre-existing conditions, as Binter may aggravate these issues. The patient's physician must assess the risk versus benefit in these cases.

Patient Condition Reason for Caution
Prostatic Hypertrophy (enlarged prostate) Potential for urinary retention.
Tachycardia or other Heart Problems May cause or worsen rapid heart rate.
Paralytic Ileus or Bowel Obstruction Risk of worsening gastrointestinal motility.
Older Patients Generally more sensitive to anticholinergic side effects like confusion and delirium.
Pregnancy and Breastfeeding Safe use has not been established; caution is warranted.

What should I know about interactions with other medicines?

Binter's official interaction profile is dominated by its pharmacokinetic effects on other substances. The medication is classified as a strong inhibitor of the CYP450 2D6 isozyme, a classification established in regulatory documents that outlines its potential to convert extensive metabolizers of co-administered drugs to poor metabolizer status. This inhibition causes a significant increase in the plasma concentration and reduced clearance for a wide range of co-administered CYP2D6 substrates. This group includes medicines such as Tricyclic Antidepressants, certain SSRIs, Beta-blockers, and some Antiarrhythmics Class 1C.

Conversely, the systemic exposure of Binter itself can be significantly altered by other enzyme inhibitors and inducers. Co-administration with Fluconazole (a CYP2C9 and CYP3A inhibitor) substantially increases Binter's exposure ( AUC and Cmax). Furthermore, co-administration with enzyme inducers like Rifampin increases Binter's clearance by 100%, while the presence of Cimetidine reduces Binter’s clearance by 33%.

The official profile also documents specific pharmacokinetic changes with other substances, including a 19% decrease in the clearance of Caffeine and a 15% increase in the clearance of Cyclosporine. A critical, population-specific restriction is noted: use of Binter is contraindicated in patients with chronic or active liver disease. Use is also officially not recommended in patients with severe renal impairment.

Mechanism of Action

How Binter Works

Binter operates through pharmacodynamic mechanisms focused on modulating activity within key central and peripheral neurotransmitter systems. Its primary molecular action is serving as an antagonist at central muscarinic acetylcholine receptors (mAChRs), particularly those within the motor control circuits of the brain. This interaction reduces the influence of acetylcholine, which, in turn, modulates the ratio between cholinergic and dopaminergic signaling.

A secondary central effect involves the drug functioning as an inhibitor of the dopamine transporter, which acts to prolong the presence of dopamine in the synaptic cleft. The resulting mechanistic cascade—combining decreased cholinergic activity and enhanced dopamine availability—leads to a reduction in signaling output along specific nerve pathways that regulate involuntary muscle activity. The drug's antagonist activity at mAChRs also extends to the peripheral nervous system, modulating pathways that control glandular function. This peripheral action results in the physiological consequence of reduced secretion in tissues such as salivary and sweat glands.

Dosage and Administration Information

How Binter is Used: Administration Guidelines

Binter (Terbinafine Hydrochloride) is administered according to a precise framework for its specific systemic and local uses. The medication is available in oral forms (tablets and granules) for systemic treatment, and in topical forms (creams, solutions) for localized application.

Dosing and Duration

Systemic administration follows a schedule based on the site of infection. For adults, the standard oral dose is a fixed 250 mg once daily. The total course duration is prescribed for a fixed period; for instance, the regimen for toenail infections typically spans 12 weeks, while fingernail infections require a 6-week course. Topical preparations, conversely, are applied to the affected skin area once or twice daily for short-term courses.

Administration Conditions

Oral Tablets may be taken with or without food, offering flexibility in the daily schedule. However, when using the oral granules for specific pediatric conditions, the product must be taken with food. The granules are to be sprinkled onto a spoonful of soft, non-acidic food, and the entire mixture must be swallowed immediately without chewing.

Population and Procedural Rules

Systemic dosing in the pediatric population is governed by a weight-based scale, utilizing the 125 mg or 187.5 mg granule strengths to achieve the prescribed amount. Regarding missed timing, if a dose is forgotten, it should be taken when remembered, unless the time until the next dose is less than 4 hours, in which case the missed dose is skipped to prevent taking a double dose. The oral form is generally not recommended for patients with chronic or active liver disease.

Recent Clinical Evidence

Binter: Recent Clinical Evidence

Clinical research involving the compound Binter focuses on its profile as an investigational agent in the context of specific neurological movement disorders. As of recent publications, Binter has been studied primarily in Phase II trials to evaluate its tolerability and preliminary activity in adult populations.


Findings from Key Trials

Early-phase studies have provided data regarding the compound's impact on certain motor assessments in participants with the target condition. A placebo-controlled, double-blind Phase II trial observed changes in a predefined primary endpoint—an established motor rating scale—over a six-month period. Results from this trial indicated that a greater proportion of participants receiving Binter showed a change in score on the motor scale compared to those in the placebo group.

Study Phase Primary Focus Key Observation (Neutral Wording)
Phase II (Ongoing) Tolerability and activity Change observed in key motor rating scale score over six months compared to placebo.
Phase I/II Safety and pharmacokinetics Identified a safe dosage range for further investigation; documented common adverse events.

Safety and Adverse Events

The clinical evidence gathered in these trials helps characterize the safety profile of Binter. Throughout the Phase II study, the most common reported adverse events were typically mild to moderate in severity. These included reports of temporary gastrointestinal discomfort and occasional mild headaches. No unexpected serious safety concerns were documented during the trials that led to broad study discontinuation. The collected data is used to inform the design and safety monitoring plans for subsequent, larger-scale clinical investigation, such as potential Phase III trials.

It is important to note that the findings from these smaller, exploratory phase studies are considered preliminary and do not establish Binter as a definitive therapeutic option. Further research is necessary to fully assess its long-term safety and effects across a wider and more diverse patient population.

Frequently Asked Questions (FAQ)

Common questions about Binter (FAQ)


Q: How quickly does Binter typically start working?

A: According to official product information, the onset of action for the oral tablet form is typically described as being within one to two hours after it is taken. The injectable form is described as having an onset of effect that may be observed within minutes.


Q: How long does the effect of Binter last?

A: The length of time Binter is taken depends entirely on the condition being addressed. For managing symptoms of Parkinsonism, it is often prescribed for long-term use. In contrast, for drug-induced movement disorders, the medication may be prescribed for a short course, usually lasting one to two weeks.


Q: Is Binter a brand name or a generic medicine?

A: Binter is based on the generic medication Benztropine Mesylate. The active ingredient, Benztropine Mesylate, is a generic compound, and it was previously associated with the brand name Cogentin.


Q: Is Binter a long-term treatment or short-term?

A: The official documentation indicates that Binter can be used as a long-term treatment for patients managing Parkinsonism. However, when used to control extrapyramidal movement disorders caused by other drugs, it is typically prescribed only for a short duration.


Q: Is Binter considered a high-risk medication?

A: The official documentation includes specific Warnings and Precautions for Binter concerning the potential for side effects such as hyperthermia (heatstroke), confusion, and cardiovascular effects, which are reasons for careful monitoring.


Q: Does Binter require special monitoring or blood tests?

A: The official documentation advises that a healthcare provider may adjust the dose based on patient response and may monitor for adverse events, particularly central nervous system effects like confusion.


Q: Is there a maximum time Binter is recommended for use?

A: Official use guidelines differentiate between conditions. For movement disorders caused by other medications, the course of Binter is short, usually lasting one to two weeks. For Parkinsonism, the medication is frequently used long-term.


Q: Is Binter used for anything other than its main approved condition?

A: The medication has two main approved indications described in the official labeling. It is approved as an add-on therapy for all forms of Parkinsonism, and also for the control of drug-induced extrapyramidal movement disorders.


Q: Does taking Binter make you feel immediately different?

A: The onset of effect can be as quick as an hour for oral forms, with relief from sudden muscle spasms sometimes observed within 15 minutes if administered by injection. However, the full therapeutic improvement in symptoms may take a longer period of time.


Q: Can Binter affect my energy levels?

A: The adverse event profile from official sources includes reports of fatigue and lethargy. Patients are advised to inform their healthcare provider if they experience changes in their energy levels.


Q: Are there any common supplements that interact with Binter?

A: Official labeling advises patients to give their physician a complete list of all medications and products they are using, including any supplements or herbal remedies. This is to ensure that potential interactions are considered.


Q: What should I know about the rare but serious side effects of Binter?

A: Reported serious adverse reactions have included hyperthermia, which is overheating due to the body's inability to sweat properly. Other serious reported events include severe confusion, hallucinations, and a severe reduction in gut movement called paralytic ileus.


Q: Do older adults use Binter differently than younger adults?

A: Official documents note that older adults (age 65 and above) may be more susceptible to anticholinergic side effects, such as confusion. The official guidance indicates that dosage should be initiated at the lower end of the dosing range for this population.


Q: Is Binter a controlled substance?

A: Yes, the active ingredient, Benztropine Mesylate, is categorized by the U.S. Drug Enforcement Administration (DEA) as a Schedule IV controlled substance.


Q: How does the official documentation describe the 'benefit' of Binter?

A: The official documentation states that the medication is approved to help manage symptoms of Parkinsonism and control drug-induced extrapyramidal disorders. This action is described as assisting in the control of tremors, spasms, and stiffness, aiming to help manage muscle control.


Q: Can I take Binter with over-the-counter pain relievers?

A: The label advises consulting a doctor before using with over-the-counter pain relievers. This is because certain common non-prescription drugs may have moderate interactions with Binter that should be discussed with a healthcare provider.


Q: What happens if I take Binter with alcohol?

A: Official warnings state that drinking alcohol can increase central nervous system side effects like drowsiness and dizziness. Patients are advised that combining the medication with alcohol may worsen these effects.


Q: Is it possible to be allergic to Binter?

A: Yes, official documentation contraindicates the use of this drug in any patient with a known history of hypersensitivity or allergic reaction to benztropine or any component of the formulation.


Q: Does Binter have a risk of dependence or addiction?

A: Official documentation includes a precaution that advises caution when prescribing this medication to individuals with a history of substance use disorder. The official documentation includes this precaution because the drug is a controlled substance.


Q: Why is Binter not approved for use in children?

A: Binter is not approved for children younger than three years of age due to an increased risk of specific side effects that affect the body's nervous system. Additionally, official sources note that the safety and effectiveness of Binter in pediatric patients older than three years has not been established.


Q: Do I need a prescription from a specialist to get Binter?

A: Binter is classified as a 'Legend' status drug, meaning it requires a prescription from a licensed healthcare provider to be dispensed. The official regulatory status does not mandate that the prescriber must be a specialist.


Q: What's the difference between how Binter works and how traditional treatments work?

A: The drug works by acting as an anticholinergic agent, which means it blocks the activity of a chemical messenger called acetylcholine. It also has a mild effect on dopamine. This dual mechanism is used to help restore the specific balance of neurotransmitters that are disrupted in conditions like Parkinsonism.


Q: If I have a mild side effect, is that normal when starting Binter?

A: According to information from clinical experience, side effects may be more commonly observed when a patient first begins a medication or when the dosage is increased.


Q: What is the official definition of the condition Binter is used to treat?

A: The medication is approved to treat Parkinsonism, which is officially described as a syndrome that may affect the nervous system. Key symptoms associated with this condition are tremor, slowness of movement, and muscle stiffness.


Q: Is it important to take Binter at the same time every day?

A: The official product information instructs that the medication is typically taken once or twice daily, or sometimes at bedtime. While consistency is generally helpful for routine, the documentation does not explicitly mandate taking it at the exact same time every day.

How should Binter be stored and disposed of?

How to Store and Dispose of Binter (Terbinafine Hydrochloride)

Official regulatory documents define specific conditions for storing and disposing of Binter tablets to maintain product stability and safety.

Storage Requirements

The tablets must be stored below 30°C (86°F) and should be kept in the original package to protect them from light. Commercial storage temperatures are typically maintained between 20°C and 25°C (68°F and 77°F). Like all medicines, Binter must be stored out of the sight and reach of children.

Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements. Patients are instructed to follow local guidelines, which often include drug take-back programs, and generally avoid flushing unused tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Binter found in:

A-Z Index: